FFA
IOVA icon

Fairfield Financial Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Fairfield Financial Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50
Closed -$308 – 315
2023
Q1 		$308 Sell
50
-117
-70% -$807 ﹤0.01% 311
2022
Q4 		$1.07K Hold
167
– – ﹤0.01% 290
2022
Q3 		$1.6K Hold
167
– – ﹤0.01% 294
2022
Q2 		$1.84K Hold
167
– – ﹤0.01% 274
2022
Q1 		$2.78K Buy
+167
New +$2.58K ﹤0.01% 276

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Fairfield Financial Advisors's IOVA Position: Q2 2023 in Review

Fairfield Financial Advisors sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 50 shares — an estimated $308 sold.

Fairfield Financial Advisors first reported a position in IOVA in Q1 2022 and held it in 5 quarters. The position peaked at $2.78K in Q1 2022. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

  • Fairfield Financial Advisors reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Fairfield Financial Advisors sold 50 Iovance Biotherapeutics shares in Q2 2023, an estimated $308.
  • Fairfield Financial Advisors first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 5 quarters.
  • Fairfield Financial Advisors's Iovance Biotherapeutics position peaked at $2.78K in Q1 2022.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Fairfield Financial Advisors's 13F filing for Q2 2023, filed 4 Nov 2024.